To Use or not to Use Anticoagulation in Patients with Advanced Malignancies? – This is the Question:

Katarzyna Rygiel

To Use or not to Use Anticoagulation in Patients with Advanced Malignancies? – This is the Question

Katarzyna Rygiel （ Department of Family Practice, Medical University of Silesia (SUM), Zabrze, Poland; 3 Maja St.; 41-800 Zabrze, Poland ）

https://doi.org/10.37155/2717-5278-0202-3

Abstract

The management of cancer-associated thrombosis (CAT) often presents challenges to members of medical teams, attending to patients with advanced malignancies. In general, indications for treatment of CAT have been driven by the randomized clinical trials (RCTs) that have usually excluded patient populations suffering from metastatic cancers, at the end-of-life period. Since the findings of such RCTs are not representative of this particular group of oncology patients, medical providers need practical help in the daily care of this population. It should be noted that venous thromboembolism (VTE) associated with cancer has been related to increased morbidity and mortality rates, as well as different symptoms that can deteriorate the patient’s quality of life (QoL). Therefore, current guidelines promote the use of anticoagulation therapy in oncology patients, focusing on the acute care contexts (e.g., a perioperative period, or chemotherapy (CHT) regimen). In contrast, in the palliative care (PC) setting, the main benefit of anticoagulation should be a reduction of symptom burden associated with VTE. However, during end-of-life care, the risk of bleeding can often overweight the potential benefits of anticoagulation. To shed some light on these complicated issues, this mini-review presents some challenges in CAT anticoagulation management. It briefly discusses VTE risk factors and therapeutic options and compares acute and PC services. This overview supports therapeutic teams in charge of oncology patients receiving PC services, where the main goal is not life extension but an assurance of the best possible QoL.

Keywords

Cancer-associated thrombosis (CAT); low molecular weight heparin (LMWH); novel oral anticoagulants (NOACs); palliative care (PC); quality of life (QoL); venous thromboembolism (VTE)

Full Text

PDF

References

[1]. Shojania KG, Duncan BW, McDonald KM, Wachter RM, Markowitz AJ Making health care safer: a critical analysis of patient safety practices. Evid Rep Technol Assess (Summ). 2001; (1–668.): i-x
[2]. Khorana AA, Carrier M, Garcia DA, Lee AY. Guidance for the prevention and treatment of cancer-associated venous thromboembolism. J Thromb Thrombolysis. 2016; 41: 81-91.
[3]. Carrier M, Khorana AA, Moretto P, Le Gal G, Karp R, Zwicker JI. Lack of evidence to support thromboprophylaxis in hospitalized medical patients with cancer. Am J Med. 2014; 127: 82-86.e1.
[4]. Rocque GB, Barnett AE, Illig LC, et al. Inpatient hospitalization of oncology patients: are we missing an opportunity for end-of-life care? J Oncol Pract. 2013; 9: 51-54.
[5]. Noble S, Johnson M. Finding the evidence for thromboprophylaxis in palliative care: first let us agree on the question. Palliat Med. 2010; 24: 359-361.
[6]. Johnson MJ, McMillan B, Fairhurst C, et al. Primary thromboprophylaxis in hospices: the association between risk of venous thromboembolism and development of symptoms. J Pain Symptom Manage. 2014; 48: 56-64.
[7]. Key NS, Khorana AA, Kuderer NM, et al. Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO clinical practice guideline update. J Clin Oncol. 2019:JCO1901461. https://ascopubs.org/doi/full/10.1200/JCO.19.01461. Accessed December 30, 2020.
[8]. Noble S. Venous thromboembolism and palliative care. Clin Med (Lond). 2019;19(4):315-318. doi:10.7861/clinmedicine.19-4-315.
[9]. White C, Noble S, Watson M, et al. Prevalence, symptom burden, and natural history of deep vein thrombosis in people with advanced cancer in specialist palliative care units (HIDDen): a prospective longitudinal observational study. Lancet Haematol. 2019;6:e79–88.
[10]. Lyons P, Verne J. Pattern of hospital admission in the final year of life. BMJ Support Palliat Care. 2011; 1: 81-82.
[11]. Macbeth F, Noble S, Evans J. Randomized phase III trial of standard therapy plus low molecular weight heparin in patients with lung cancer: FRAGMATIC Trial. J Clin Oncol. 2016;34:488–494.
[12]. Maraveyas A, Waters J, Roy R. Gemcitabine versus gemcitabine plus dalteparin thromboprophylaxis in pancreatic cancer. Eur J Cancer. 2012;48:1283–1292.
[13]. Al-Samkari H, Connors JM. The role of direct oral anticoagulants in treatment of cancer-associated thrombosis. Cancers (Basel). 2018;10(8).
[14]. Ay C , Beyer-Westendorf J, Pabinger I. Treatment of cancer-associated venous thromboembolism in the age of direct oral anticoagulants. Ann Oncol. 2019; 30(6): 897–907.
[15]. Lee AY, Carrier M. Treatment of cancer-associated thrombosis: perspectives on the use of novel oral anticoagulants. Thromb Res. 2014;133 Suppl 2:S167-71.
[16]. Samuelson Bannow BT, Lee A, Khorana AA, Zwicker JI, Noble S, Ay C, Carrier M. Management of cancer-associated thrombosis in patients with thrombocytopenia: guidance from the SSC of the ISTH. J Thromb Haemost. 2018;16(6):1246-1249.
[17]. Carrier M, Khorana AA, Zwicker J, et al. Management of challenging cases of patients with cancer-associated thrombosis including recurrent thrombosis and bleeding: guidance from the SSC of the ISTH. J Thromb Haemost. 2013;11:1760–5.
[18]. Lee AY, Kamphuisen PW, Meyer G, et al. Tinzaparin vs Warfarin for treatment of acute venous thromboembolism in patients with active cancer: a randomized clinical trial. JAMA. 2015;314(7):677–686.
[19]. Lee AY, Levine MN, Baker RI, et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med. 2003;349(2):146–153.
[20]. Raskob GE, van Es N, Verhamme P, et al; Hokusai VTE Cancer Investigators. Edoxaban for the treatment of cancer-associated venous thromboembolism. N Engl J Med. 2018;378:615-624.
[21].Young AM, Marshall A, Thirlwall J, et al. Comparison of an oral factor Xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a randomized trial (SELECT-D). J Clin Oncol. 2018:36:2017-2023.
[22]. McBane RD 2nd, Wysokinski WE, Le-Rademacher JG. Apixaban and dalteparin in active malignancy-associated venous thromboembolism: the ADAM VTE trial. J Thromb Haemost. 2020;18:411-421.
[23]. Agnelli G, Becattini C, Meyer G, et al; Caravaggio Investigators. Apixaban for the treatment of venous thromboembolism associated with cancer. N Engl J Med. 2020;382(17):1599-1607.
[24]. Kimpton M, Wells PS, Carrier M. Apixaban for the prevention of venous thromboembolism in high-risk ambulatory cancer patients receiving chemotherapy: Rational and design of the AVERT trial. Thromb Res. 2018;164:S124-S129.
[25]. Khorana AA, Vadhan-Raj S, Kuderer NM, et al. Rivaroxaban for preventing venous thromboembolism in high-risk ambulatory patients with cancer: rationale and design of the CASSINI trial. Rationale and design of the CASSINI trial. Thromb Haemost. 2017;117:2135-2145.
[26]. Noble S, Banerjee S, Pease N. Anticoagulation for cancer associated thrombosis at the end of life: review of a case series of 214 patients. Palliat Med. 2018;32(1S):47–8.
[27]. Venous Thromboembolism in over 16s: Reducing the Risk of Hospital-Acquired Deep Vein Thrombosis or Pulmonary Embolism. National Institute for Health and Care Excellence (NICE); London, UK: 2018. [(accessed on 30 December 2020)]. Available online: https://www.nice.org.uk/guidance/ng89.
[28]. Monreal M., Falga C., Valdes M., Suarez C., Gabriel F., Tolosa C., Montes J. Fatal pulmonary embolism and fatal bleeding in cancer patients with venous thromboembolism: Findings from the RIETE registry. J. Thromb. Haemost. 2006;4:1950–1956.
[29]. Weber C., Merminod T., Herrmann F.R., Zulian G.B. Prophylactic anti-coagulation in cancer palliative care: A prospective randomised study. Support. Care Cancer. 2008;16:847–852.
[30]. Tardy B, Piccard S, Guirimand F, et al. Bleeding risk of terminally ill patients hospitalized in palliative care units: the RHESO study. J Thromb Haemost. 2017; 15: 420-428.
[31]. Hisada Y, Mackman N. Cancer-associated pathways and biomarkers of venous thrombosis. Blood. 2017;130(13):1499-1506.
[32]. Riedl J, Preusser M, Nazari PM, et al. Podoplanin expression in primary brain tumors induces platelet aggregation and increases risk of venous thromboembolism. Blood. 2017;129(13):1831-1839.

Publishing time:2020-12-10
This work is licensed under a Creative Commons Attribution 4.0 International License